Osang Healthcare Co.,Ltd (036220.KQ)
KRW 11870.0
(-2.63%)
KRW 11870.0
(-2.63%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 157.89 Billion KRW | 172.74% |
| 2022 | 57.01 Billion KRW | 1529.83% |
| 2021 | 3.09 Billion KRW | -102.33% |
| 2020 | 157.64 Billion KRW | 14839.25% |
| 2019 | 1.08 Billion KRW | -69.85% |
| 2018 | 4.01 Billion KRW | -21.45% |
| 2017 | 1.26 Billion KRW | 8.26% |
| 2016 | 4.09 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -2.77 Billion KRW | -354.48% |
| 2024 Q1 | -3.48 Billion KRW | 120.39% |
| 2023 Q1 | 156.83 Billion KRW | 8772.52% |
| 2023 Q4 | -6.79 Billion KRW | -3.5% |
| 2023 Q3 | -6.56 Billion KRW | -254.4% |
| 2023 Q2 | 4.25 Billion KRW | -97.29% |
| 2023 FY | - KRW | 172.74% |
| 2022 Q2 | 17.19 Billion KRW | -48.95% |
| 2022 FY | - KRW | 1529.83% |
| 2022 Q4 | 1.76 Billion KRW | 6.15% |
| 2022 Q3 | 1.66 Billion KRW | -90.32% |
| 2022 Q1 | 33.68 Billion KRW | 473.27% |
| 2021 Q3 | 1.34 Billion KRW | 0.0% |
| 2021 FY | - KRW | -102.33% |
| 2021 Q4 | -9.02 Billion KRW | -770.81% |
| 2020 FY | - KRW | 14839.25% |
| 2019 FY | - KRW | -69.85% |
| 2018 FY | - KRW | -21.45% |
| 2017 FY | - KRW | 8.26% |
| 2016 FY | - KRW | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| InBody Co.,Ltd | 44.25 Billion KRW | -256.744% |
| Curexo Inc. | -2.75 Billion KRW | 5833.815% |
| Seegene, Inc. | 35.65 Billion KRW | -342.816% |
| i-SENS, Inc. | 24.14 Billion KRW | -553.925% |
| Ray Co., Ltd. | 7.62 Billion KRW | -1970.897% |
| Gencurix Inc. | -18.09 Billion KRW | 972.661% |
| Sugentech Inc. | -12.13 Billion KRW | 1401.485% |
| L&C Bio Co., Ltd | 13.4 Billion KRW | -1078.079% |